Quality of Life Analysis of Treatment in Patients With Prostate Cancer on Adjuvant Zoladex Therapy

Quality of Life Analysis of Prostate Cancer Patient's Therapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00692874

Acronym

AZTEK EXT

Enrollment

1646

Registered

2008-06-06

Start date

2008-06-30

Completion date

2010-09-30

Last updated

2010-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

Quality of Life

Brief summary

This is an open label, non-interventional quality of life analysis for Zoladex treated prostate cancer patients by investigator's questionnaire

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Healthy volunteers

Inclusion criteria

* Provision of informed consent * Early or locally-advanced prostate cancer patients on androgen deprivation therapy * Investigators are requested to recruit patients only with at least 1 month prior Zoladex treatment.

Exclusion criteria

* Allergy to substance of medication * Prostate cancer patients with advanced disease

Design outcomes

Primary

Measure	Time frame
Elements of a general and three disease-specific investigator questionnaire	Quarterly (plus or minus 3 days )

Secondary

Measure	Time frame
Investigator Assessment Report	Yearly (plus or minus 1 week )

Countries

Hungary

Outcome results